Table 1 Baseline characteristics of the study population
Variables | SLE patients (n = 10,013) |
|---|---|
Age, years | 36.9 ± 15.2 |
-19 | 851 (8.5) |
20–29 | 2,578 (25.7) |
30–39 | 2,468 (24.6) |
40–49 | 2,132 (21.3) |
50–59 | 1,202 (12.0) |
60–69 | 456 (4.6) |
70–79 | 326 (3.3) |
Sex, female | 9,109 (91.0) |
Payer type | |
National health insurance | 8,886 (88.7) |
Medical aid | 1,127 (11.3) |
Charlson comorbidity index | 1 ± 1.2 |
Comorbidities | |
Hypertension | 856 (8.5) |
Diabetes mellitus | 68 (0.7) |
Hyperlipidemia | 341 (3.4) |
Chronic kidney disease | 142 (1.4) |
SLE-related comorbidities | |
Anti-phospholipid antibody syndrome | 6 (0.1) |
Fibromyalgia | 25 (0.2) |
Avascular necrosis | 76 (0.8) |
Interstitial lung disease | 50 (0.5) |
Viral infection | |
Herpes zoster | 138 (1.4) |
CMV | 7 (0.1) |
Medicationa | |
Hydroxychloroquine | 5,755 (57.5) |
Glucocorticoid | 6,359 (63.5) |
NSAIDs | 2,103 (21.0) |